-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$10.75154.14% Upside
Aclaris Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Aclaris Therapeutics, Inc.?
Aclaris Therapeutics, Inc. has been rated by research analysts at BTIG, Jefferies, Stifel Nicolaus, Goldman Sachs in the past 90 days.